Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.

Gordon SC, Villamil A, Jacobson IM, Lawitz EJ, Younes Z, Silveira MG, Bowlus CL, Drenth JPH, Vierling JM, Morgera U, Vasura A, Dalekos G, Galli A, Rabinovitz M, Heo J, Nevens F, Levy C, Zhou Y, Carroll S, Crittenden DB

Open source

DOI: 10.1097/hc9.0000000000000918
Published: 2026 May 1
Container: Hepatology communications
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/hc9.0000000000000918,
  title = {Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.},
  author = {Gordon SC and Villamil A and Jacobson IM and Lawitz EJ and Younes Z and Silveira MG and Bowlus CL and Drenth JPH and Vierling JM and Morgera U and Vasura A and Dalekos G and Galli A and Rabinovitz M and Heo J and Nevens F and Levy C and Zhou Y and Carroll S and Crittenden DB},
  year = {2026},
  journal = {Hepatology communications},
  doi = {10.1097/hc9.0000000000000918},
  url = {https://doi.org/10.1097/hc9.0000000000000918}
}

RIS

TY  - JOUR
TI  - Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.
AU  - Gordon SC
AU  - Villamil A
AU  - Jacobson IM
AU  - Lawitz EJ
AU  - Younes Z
AU  - Silveira MG
AU  - Bowlus CL
AU  - Drenth JPH
AU  - Vierling JM
AU  - Morgera U
AU  - Vasura A
AU  - Dalekos G
AU  - Galli A
AU  - Rabinovitz M
AU  - Heo J
AU  - Nevens F
AU  - Levy C
AU  - Zhou Y
AU  - Carroll S
AU  - Crittenden DB
PY  - 2026
JO  - Hepatology communications
DO  - 10.1097/hc9.0000000000000918
UR  - https://doi.org/10.1097/hc9.0000000000000918
ER  -

APA

SC, G., A, V., IM, J., EJ, L., Z, Y., MG, S., CL, B., JPH, D., JM, V., U, M., A, V., G, D., A, G., M, R., J, H., F, N., C, L., Y, Z., S, C., & DB, C. (2026). Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.. Hepatology communications. https://doi.org/10.1097/hc9.0000000000000918

Source records

pubmed · retrieved 2026-09-27T12:01:42.401Z
europe-pmc · retrieved 2026-09-27T12:01:42.406Z